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CAD = coronary artery disease.
ELITE II = Losartan Heart Failure Survival Study; GISSI = Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico.
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Lipid-lowering treatment with statins clearly reduces
morbidity and mortality of patients with documented CAD
[1–3]. However, because these trial protocols excluded
patients with chronic heart failure, information on the effect of
statins in this clinical condition is incomplete.
Since the prevalent etiology of heart failure is CAD, its
prevention may reduce heart failure progression. Consistent
with this hypothesis, a subanalysis of the Scandinavian
Simvastatin Survival Study showed that statin treatment
could prevent the occurrence of overt heart failure in patients
with CAD [4].
Furthermore, recent studies suggest that statin treatment
may have other beneficial effects besides cholesterol
lowering. It has been hypothesized that the inhibition of
hydroxymethyl glutaryl coenzyme A reductase can interfere
with the synthesis of anti-inflammatory components, thus
downregulating cytokine and chemokine production, which is
activated in patients with heart failure (due to any etiology)
[5]. Statin treatment can also improve endothelial function,
largely compromised in patients with heart failure irrespective
of the underlying etiology, and is considered responsible for
multi-organ failure [6,7].
Along with this encouraging evidence, there are some
suggestions that low levels of circulating lipoproteins and
cholesterol may be independent predictors of impaired
outcome in patients with heart failure [8,9]. An association
between a cholesterol cutoff level below 5.2 mmol/L
(according to the treatment guidelines of the American Heart
Association) and impaired 1-year event free survival was
found in a group of patients with heart failure [10]. There are
several possible explanations for this finding. High levels of
cholesterol can be beneficial in heart failure patients;
cholesterol-rich serum lipoproteins are able to modulate
inflammatory immune function because they bind and detoxify
bacterial lipopolysaccharide, whose production is increased
in heart failure patients (endotoxin–lipoprotein hypothesis)
[10]. Lipopolysaccharide is a very strong stimulator of the
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Abstract
Statins reduce mortality of patients with coronary artery disease (CAD). However, by protocol, trials
have excluded patients with chronic heart failure. Since the prevalent etiology of heart failure is CAD,
preventing CAD may prevent heart failure progression. Statins may have other beneficial effects
besides cholesterol lowering, such as anti-inflammatory properties and improvement of endothelial
function. On the contrary, high levels of cholesterol can be beneficial in heart failure patients on the
basis of the ability of serum lipoproteins to modulate inflammatory response. Furthermore, statins
affecting mitochondrial function can have a deleterious effect on skeletal or cardiac muscles. Despite
all these conflicting data, there is no evidence from trials on the effects of statins in patients with heart
failure. For this reason, the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico
(GISSI) investigators planned a controlled trial testing the effect of statins in patients with heart failure
of different etiology.
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release of proinflammatory cytokines that promote heart
failure progression and death.
Statins also inhibit the synthesis of mevalonate, a precursor
of ubiquinone, which is a central compound of the
mitochondrial respiratory chain [11–13]. Statins thus affect
mitochondrial function and can have deleterious effects on
skeletal or cardiac muscles. This mechanism may also be the
basis of the main adverse effect of statins, which is toxic
myopathy, possibly related to mitochondrial dysfunction.
Besides heart failure syndrome, other evidence also
discourages the use of lipid-lowering agents in elderly
patients; and patients affected by heart failure are generally
old. An analysis of the Framingham database showed that the
relationship between total cholesterol levels and all-cause
mortality was positive at age 40 years, negligible at
50–70 years old, and negative at age 80 years [14]. For this
reason, Kronmal et al. stated that physicians should be
cautious about initiating cholesterol-lowering treatment in
patients older than 70 years of age. They furthermore felt that
only randomized clinical trials in older people could settle the
debate over the efficacy of lipid-lowering interventions for
reducing mortality and morbidity in elderly patients. In this
context, it is important to remember that the mean age of
patients with heart failure is approximately 65 years, as
determined from trial databases, and the mean age is older
than 70 years in community settings.
Even though there is both encouraging and discouraging
scientific information, there is no direct evidence from
randomized clinical trials on the effects of statins in patients
with heart failure. Only post hoc analyses have been
performed.
The Losartan Heart Failure Survival Study (ELITE II) showed
a mortality reduction in patients with heart failure of any
etiology treated with statins (nonrandomized comparison)
[15]. Of nearly 900 patients with left ventricular
dysfunction/failure enrolled in the statin hypothesis of the
Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto
Miocardico (GISSI)-Prevenzione trial, no safety problems
were observed in the patients allocated to pravastatin [16].
Additionally, the favorable direction of the effect in terms of
total mortality was similar among patients with and without
left ventricular dysfunction and/or failure (unpublished data).
In conclusion, while there are no reliable clinical data on the
benefit/risk profile of statins in heart failure, current
knowledge is characterized by some suggestive observations
supporting the benefit of statins but also by conflicting
clinical and experimental evidence on their use. This can be
considered the ideal scenario to formally test the hypothesis.
For these reasons, the GISSI investigators planned a
randomized clinical trial testing the effect of statins in
patients with heart failure of any etiology. The main objective
was to demonstrate whether long-term treatment with statins
is able to reduce major clinical events such as all-cause
mortality, and hospitalizations for any cause, that frequently
affect this clinical condition.
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